ImmunityBio, Inc. · Transaction Mar 6, 2023 · Filed Apr 17, 2023 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · IBRX
-1.49% · -$0.1400 · Vol 2.5M
Live · updated 10:55:47 ET
Immunitybio Inc
Biotechnology
$9.61
Follow $IBRX
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $IBRX by emailVeridion Score
BETAMEDIUM CONF · 6 of 6 factors measuredWed Oct 7 · last completed session · daily score · 15h old · IBRX
MethodologyIBRX
Immunitybio Inc
Wed Oct 7 · last completed session · daily score · 15h old
Middle range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
48/ 100
Veridion Score
Middle range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Wed Oct 7 · last completed session · daily score · 15h old
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is IBRX moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Immunitybio Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Listed since
2021
Employees
691
Country
US
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$9.63
Day high
$9.72
Day low
$9.43
Previous close
$9.75
52W high
$11.55
-16.84% from high
52W low
$1.98
80% of range
Market cap
$10.3B
EPS
$-1.0100
Beta
1.14
Shares out
1.1B
Volume
2.5M
0.21× rel vol
Avg volume
12M
VWAP
$9.58
Price history computed in-house
1W
+3.50%
1M
+15.86%
3M
+16.85%
1Y
+279.64%
YTD
+385.10%
SMA 50 $8.17 · above
SMA 200 $7.32 · above
52W position 80%
IBRX overview
Related filings and maps
Public disclosures
Congress activity in IBRX
1 filers · 0 buys · 1 sells (0 labeled S (partial)) · Mar 6, 2023 to Mar 6, 2023 · House 1 / Senate 0
All available history · Latest 1 of 1 lines · Read 2026-10-08T14:55:50.976Z
Official filing ↗
Federal contracts
IBRX contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for IBRX in this window.
Lobbying spend
IBRX lobbying filings, year to date.
Registered lobbying filings matched to Immunitybio Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for IBRX in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for IBRX.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.